In this episode of "The Top Line," we talk with Fierce’s Andrea Park and Gabrielle Masson about the latest from the American Diabetes Association's annual conference. We also cover a statement about transgender care, light therapy, and the rest of the week's headlines. 

To learn more about the topics in this episode:

• 'Podnosis': Medicaid eligibility determinations, healthcare for the LGBTQ+ community
• Introducing the Fierce 50: Honoring healthcare and biopharma champions fighting for patient care
• Lilly links oral obesity drug to 15% weight loss, setting bar for Pfizer in blockbuster battle
• Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
• UPDATE: Lilly's next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz
• Let there be light: Scientists report new progress in quest to treat afib with optogenetics
• UK's flagging clinical trial sector faces fresh challenge as National Cancer Research Institute set to close
• Biotech leaders protest 'actively harmful' bans on gender-affirming care
• Know Labs unveils first prototype of portable, noninvasive glucose monitor
• Embecta dives deeper into Type 2 diabetes tech with Tidepool team-up
• Fitterfly's diabetes digital therapeutic cuts blood sugar, weight in real-world trial

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

We’d love to hear from you! If you have a comment about this podcast or if you have a tip for a future episode of The Top Line, you can reach us at this link.